SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-018715
Filing Date
2024-01-30
Accepted
2024-01-30 07:10:30
Documents
16
Period of Report
2024-01-29
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d114617d8k.htm   iXBRL 8-K 29330
2 EX-3.1 d114617dex31.htm EX-3.1 37807
3 EX-3.2 d114617dex32.htm EX-3.2 176041
  Complete submission text file 0001193125-24-018715.txt   422415

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA cgon-20240129.xsd EX-101.SCH 2877
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE cgon-20240129_lab.xml EX-101.LAB 19482
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cgon-20240129_pre.xml EX-101.PRE 12171
17 EXTRACTED XBRL INSTANCE DOCUMENT d114617d8k_htm.xml XML 3975
Mailing Address 400 SPECTRUM CENTER DRIVE SUITE 2040 IRVINE CA 92618
Business Address 400 SPECTRUM CENTER DRIVE SUITE 2040 IRVINE CA 92618 (949) 419-6203
CG Oncology, Inc. (Filer) CIK: 0001991792 (see all company filings)

IRS No.: 371611499 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41925 | Film No.: 24575798
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)